Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV
Status:
Terminated
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine safety and efficacy of 30 mg daily dose of
clevudine (L-FMAU) at 24 weeks of treatment in patients with chronic HBV.